Vir Biotechnology Inc at Morgan Stanley Global Healthcare Conference Transcript
Good afternoon, everyone. I'm Andrew Galler, one of the biotech analysts here at Morgan Stanley. And I'm pleased to be joined by Phil Pang from Vir Biotechnology. Phil is the CMO and Interim Head of Research currently. And before we get jump in, I'm going to read some disclosure statements.
For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Questions & Answers
So, I guess that we can start very broadly, right now. Vir now has a healthy balance sheet given the [Zabouti] windfall. So maybe we could discuss capital allocation priorities broadly.
Thank you, Andrew. So, I think that the key here is not just
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |